SG183696A1 - Medicaments comprising nepicastat for use in treating dependence on a substance - Google Patents

Info

Publication number

SG183696A1

SG183696A1 SG2012058210A SG2012058210A SG183696A1 SG 183696 A1 SG183696 A1 SG 183696A1 SG 2012058210 A SG2012058210 A SG 2012058210A SG 2012058210 A SG2012058210 A SG 2012058210A SG 183696 A1 SG183696 A1 SG 183696A1

Authority

SG

Singapore

Prior art keywords

nepicastat

treatment

vehicle

animals

dose

Prior art date

2007-08-06

Links

• Espacenet
• Global Dossier
• Discuss

• 239000000126 substance Substances 0.000 title claims abstract description 85
• 229950005868 nepicastat Drugs 0.000 title claims description 272
• YZZVIKDAOTXDEB-JTQLQIEISA-N nepicastat Chemical compound NCC1=CNC(=S)N1[C@@H]1CC2=CC(F)=CC(F)=C2CC1 YZZVIKDAOTXDEB-JTQLQIEISA-N 0.000 title claims description 269
• 239000003814 drug Substances 0.000 title claims description 89
• 229940126062 Compound A Drugs 0.000 claims abstract description 124
• NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 claims abstract description 124
• 208000011117 substance-related disease Diseases 0.000 claims abstract description 114
• 238000000034 method Methods 0.000 claims abstract description 113
• 208000024891 symptom Diseases 0.000 claims abstract description 96
• 208000022497 Cocaine-Related disease Diseases 0.000 claims abstract description 50
• 201000006152 substance dependence Diseases 0.000 claims abstract description 45
• 206010013663 drug dependence Diseases 0.000 claims abstract description 35
• 201000006145 cocaine dependence Diseases 0.000 claims abstract description 33
• ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 claims description 383
• VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 claims description 201
• 229960003920 cocaine Drugs 0.000 claims description 191
• 238000011282 treatment Methods 0.000 claims description 161
• 230000000694 effects Effects 0.000 claims description 149
• 239000003795 chemical substances by application Substances 0.000 claims description 99
• 229960003638 dopamine Drugs 0.000 claims description 98
• 241001465754 Metazoa Species 0.000 claims description 91
• 229940079593 drug Drugs 0.000 claims description 87
• SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 claims description 85
• SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 claims description 85
• 229960002748 norepinephrine Drugs 0.000 claims description 85
• 239000003981 vehicle Substances 0.000 claims description 79
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 72
• 201000009032 substance abuse Diseases 0.000 claims description 72
• 230000036961 partial effect Effects 0.000 claims description 58
• 241000700159 Rattus Species 0.000 claims description 56
• 230000004044 response Effects 0.000 claims description 52
• 150000001875 compounds Chemical class 0.000 claims description 48
• BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 claims description 48
• 238000011699 spontaneously hypertensive rat Methods 0.000 claims description 45
• 238000012360 testing method Methods 0.000 claims description 45
• QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 claims description 38
• 241000282472 Canis lupus familiaris Species 0.000 claims description 37
• 210000001519 tissue Anatomy 0.000 claims description 33
• 235000019788 craving Nutrition 0.000 claims description 31
• 230000000306 recurrent effect Effects 0.000 claims description 31
• 239000000203 mixture Substances 0.000 claims description 30
• 239000005557 antagonist Substances 0.000 claims description 29
• YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 27
• 230000006735 deficit Effects 0.000 claims description 27
• 230000002829 reductive effect Effects 0.000 claims description 26
• 230000002459 sustained effect Effects 0.000 claims description 26
• 230000001965 increasing effect Effects 0.000 claims description 25
• 239000003112 inhibitor Substances 0.000 claims description 25
• 230000002093 peripheral effect Effects 0.000 claims description 25
• OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 claims description 24
• 230000003276 anti-hypertensive effect Effects 0.000 claims description 24
• 229960003692 gamma aminobutyric acid Drugs 0.000 claims description 24
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 22
• 230000036772 blood pressure Effects 0.000 claims description 21
• 230000037396 body weight Effects 0.000 claims description 21
• -1 polyethylene Polymers 0.000 claims description 21
• 206010013654 Drug abuse Diseases 0.000 claims description 20
• 102000004190 Enzymes Human genes 0.000 claims description 20
• 108090000790 Enzymes Proteins 0.000 claims description 20
• BRUQQQPBMZOVGD-XFKAJCMBSA-N Oxycodone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(OC)C2=C5[C@@]13CCN4C BRUQQQPBMZOVGD-XFKAJCMBSA-N 0.000 claims description 20
• 230000008033 biological extinction Effects 0.000 claims description 20
• 230000002354 daily effect Effects 0.000 claims description 20
• 210000003975 mesenteric artery Anatomy 0.000 claims description 20
• SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 claims description 19
• 238000004458 analytical method Methods 0.000 claims description 19
• 210000004369 blood Anatomy 0.000 claims description 19
• 239000008280 blood Substances 0.000 claims description 19
• 210000003710 cerebral cortex Anatomy 0.000 claims description 19
• UHOVQNZJYSORNB-UHFFFAOYSA-N monobenzene Natural products C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims description 19
• 229960002715 nicotine Drugs 0.000 claims description 19
• SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 claims description 19
• 239000000243 solution Substances 0.000 claims description 19
• 230000002085 persistent effect Effects 0.000 claims description 18
• 241000208125 Nicotiana Species 0.000 claims description 17
• 235000002637 Nicotiana tabacum Nutrition 0.000 claims description 17
• 239000000556 agonist Substances 0.000 claims description 17
• 239000002767 noradrenalin uptake inhibitor Substances 0.000 claims description 17
• 229940127221 norepinephrine reuptake inhibitor Drugs 0.000 claims description 17
• YNQLUTRBYVCPMQ-UHFFFAOYSA-N Ethylbenzene Chemical compound CCC1=CC=CC=C1 YNQLUTRBYVCPMQ-UHFFFAOYSA-N 0.000 claims description 16
• 150000003943 catecholamines Chemical class 0.000 claims description 16
• 201000001272 cocaine abuse Diseases 0.000 claims description 16
• 239000002532 enzyme inhibitor Substances 0.000 claims description 16
• 229940125532 enzyme inhibitor Drugs 0.000 claims description 16
• ZQBFAOFFOQMSGJ-UHFFFAOYSA-N hexafluorobenzene Chemical compound FC1=C(F)C(F)=C(F)C(F)=C1F ZQBFAOFFOQMSGJ-UHFFFAOYSA-N 0.000 claims description 16
• 210000005240 left ventricle Anatomy 0.000 claims description 16
• 230000004060 metabolic process Effects 0.000 claims description 16
• 229940076279 serotonin Drugs 0.000 claims description 16
• 230000007423 decrease Effects 0.000 claims description 15
• 230000003993 interaction Effects 0.000 claims description 15
• 230000009467 reduction Effects 0.000 claims description 15
• 229940124834 selective serotonin reuptake inhibitor Drugs 0.000 claims description 15
• 239000012896 selective serotonin reuptake inhibitor Substances 0.000 claims description 15
• 238000012549 training Methods 0.000 claims description 15
• KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical group C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 claims description 14
• 208000019901 Anxiety disease Diseases 0.000 claims description 14
• 206010022998 Irritability Diseases 0.000 claims description 14
• 239000000935 antidepressant agent Substances 0.000 claims description 14
• 229940005513 antidepressants Drugs 0.000 claims description 14
• 230000015572 biosynthetic process Effects 0.000 claims description 14
• 238000002474 experimental method Methods 0.000 claims description 14
• 239000003368 psychostimulant agent Substances 0.000 claims description 14
• 150000003839 salts Chemical class 0.000 claims description 14
• VAYOSLLFUXYJDT-RDTXWAMCSA-N Lysergic acid diethylamide Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N(CC)CC)C2)=C3C2=CNC3=C1 VAYOSLLFUXYJDT-RDTXWAMCSA-N 0.000 claims description 13
• 239000000674 adrenergic antagonist Substances 0.000 claims description 13
• 230000001430 anti-depressive effect Effects 0.000 claims description 13
• 230000001419 dependent effect Effects 0.000 claims description 13
• 229950002454 lysergide Drugs 0.000 claims description 13
• JTJMJGYZQZDUJJ-UHFFFAOYSA-N phencyclidine Chemical compound C1CCCCN1C1(C=2C=CC=CC=2)CCCCC1 JTJMJGYZQZDUJJ-UHFFFAOYSA-N 0.000 claims description 13
• 206010002942 Apathy Diseases 0.000 claims description 12
• 102000012289 Corticotropin-Releasing Hormone Human genes 0.000 claims description 12
• 108010022152 Corticotropin-Releasing Hormone Proteins 0.000 claims description 12
• 239000000055 Corticotropin-Releasing Hormone Substances 0.000 claims description 12
• 241001539473 Euphoria Species 0.000 claims description 12
• 206010015535 Euphoric mood Diseases 0.000 claims description 12
• 229940123685 Monoamine oxidase inhibitor Drugs 0.000 claims description 12
• CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical group CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 claims description 12
• URLKBWYHVLBVBO-UHFFFAOYSA-N Para-Xylene Chemical group CC1=CC=C(C)C=C1 URLKBWYHVLBVBO-UHFFFAOYSA-N 0.000 claims description 12
• 238000000540 analysis of variance Methods 0.000 claims description 12
• 230000003247 decreasing effect Effects 0.000 claims description 12
• 238000011161 development Methods 0.000 claims description 12
• 231100000673 dose–response relationship Toxicity 0.000 claims description 12
• IVSZLXZYQVIEFR-UHFFFAOYSA-N m-xylene Chemical group CC1=CC=CC(C)=C1 IVSZLXZYQVIEFR-UHFFFAOYSA-N 0.000 claims description 12
• 238000012423 maintenance Methods 0.000 claims description 12
• 239000002899 monoamine oxidase inhibitor Substances 0.000 claims description 12
• 230000003542 behavioural effect Effects 0.000 claims description 11
• 238000001543 one-way ANOVA Methods 0.000 claims description 11
• 229940044551 receptor antagonist Drugs 0.000 claims description 11
• 239000002464 receptor antagonist Substances 0.000 claims description 11
• 230000002861 ventricular Effects 0.000 claims description 11
• USSIQXCVUWKGNF-UHFFFAOYSA-N 6-(dimethylamino)-4,4-diphenylheptan-3-one Chemical compound C=1C=CC=CC=1C(CC(C)N(C)C)(C(=O)CC)C1=CC=CC=C1 USSIQXCVUWKGNF-UHFFFAOYSA-N 0.000 claims description 10
• 239000003136 dopamine receptor stimulating agent Substances 0.000 claims description 10
• 238000009472 formulation Methods 0.000 claims description 10
• 229960001797 methadone Drugs 0.000 claims description 10
• 239000004050 mood stabilizer Substances 0.000 claims description 10
• 229940127237 mood stabilizer Drugs 0.000 claims description 10
• 239000003402 opiate agonist Substances 0.000 claims description 10
• 239000003401 opiate antagonist Substances 0.000 claims description 10
• 238000003786 synthesis reaction Methods 0.000 claims description 10
• SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 claims description 9
• WPMVQUHUCQAOBU-UHFFFAOYSA-N 3-[(3,5-difluorophenyl)methyl]-1h-imidazole-2-thione Chemical compound FC1=CC(F)=CC(CN2C(=NC=C2)S)=C1 WPMVQUHUCQAOBU-UHFFFAOYSA-N 0.000 claims description 9
• 235000001674 Agaricus brunnescens Nutrition 0.000 claims description 9
• 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims description 9
• DUGOZIWVEXMGBE-UHFFFAOYSA-N Methylphenidate Chemical compound C=1C=CC=CC=1C(C(=O)OC)C1CCCCN1 DUGOZIWVEXMGBE-UHFFFAOYSA-N 0.000 claims description 9
• 229940123257 Opioid receptor antagonist Drugs 0.000 claims description 9
• 229940121991 Serotonin and norepinephrine reuptake inhibitor Drugs 0.000 claims description 9
• 230000001154 acute effect Effects 0.000 claims description 9
• 239000000695 adrenergic alpha-agonist Substances 0.000 claims description 9
• 229940025084 amphetamine Drugs 0.000 claims description 9
• 230000001773 anti-convulsant effect Effects 0.000 claims description 9
• 230000000561 anti-psychotic effect Effects 0.000 claims description 9
• 239000001961 anticonvulsive agent Substances 0.000 claims description 9
• 229960003965 antiepileptics Drugs 0.000 claims description 9
• 102000012740 beta Adrenergic Receptors Human genes 0.000 claims description 9
• 108010079452 beta Adrenergic Receptors Proteins 0.000 claims description 9
• 230000003920 cognitive function Effects 0.000 claims description 9
• 239000002288 dopamine 2 receptor stimulating agent Substances 0.000 claims description 9
• 230000003400 hallucinatory effect Effects 0.000 claims description 9
• 229960001344 methylphenidate Drugs 0.000 claims description 9
• 239000000181 nicotinic agonist Substances 0.000 claims description 9
• 102000005962 receptors Human genes 0.000 claims description 9
• 108020003175 receptors Proteins 0.000 claims description 9
• 239000003775 serotonin noradrenalin reuptake inhibitor Substances 0.000 claims description 9
• 208000019116 sleep disease Diseases 0.000 claims description 9
• GOYDNIKZWGIXJT-UHFFFAOYSA-N 1,2-difluorobenzene Chemical compound FC1=CC=CC=C1F GOYDNIKZWGIXJT-UHFFFAOYSA-N 0.000 claims description 8
• KWTSXDURSIMDCE-UHFFFAOYSA-N 1-phenylpropan-2-amine Chemical group CC(N)CC1=CC=CC=C1 KWTSXDURSIMDCE-UHFFFAOYSA-N 0.000 claims description 8
• YEJRWHAVMIAJKC-UHFFFAOYSA-N 4-Butyrolactone Chemical compound O=C1CCCO1 YEJRWHAVMIAJKC-UHFFFAOYSA-N 0.000 claims description 8
• 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims description 8
• 241000218236 Cannabis Species 0.000 claims description 8
• 229940122459 Glutamate antagonist Drugs 0.000 claims description 8
• ZPXSCAKFGYXMGA-UHFFFAOYSA-N Mazindol Chemical compound N12CCN=C2C2=CC=CC=C2C1(O)C1=CC=C(Cl)C=C1 ZPXSCAKFGYXMGA-UHFFFAOYSA-N 0.000 claims description 8
• 206010028813 Nausea Diseases 0.000 claims description 8
• 239000008896 Opium Substances 0.000 claims description 8
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 8
• 230000036506 anxiety Effects 0.000 claims description 8
• 230000001684 chronic effect Effects 0.000 claims description 8
• 230000003205 diastolic effect Effects 0.000 claims description 8
• 239000012458 free base Substances 0.000 claims description 8
• 239000003825 glutamate receptor antagonist Substances 0.000 claims description 8
• 239000000380 hallucinogen Substances 0.000 claims description 8
• 230000008693 nausea Effects 0.000 claims description 8
• 229960001027 opium Drugs 0.000 claims description 8
• 239000008188 pellet Substances 0.000 claims description 8
• 229950010883 phencyclidine Drugs 0.000 claims description 8
• 229940125794 sodium channel blocker Drugs 0.000 claims description 8
• 239000003195 sodium channel blocking agent Substances 0.000 claims description 8
• 239000011780 sodium chloride Substances 0.000 claims description 8
• 229940127291 Calcium channel antagonist Drugs 0.000 claims description 7
• 229940122439 Hydroxylase inhibitor Drugs 0.000 claims description 7
• 206010047700 Vomiting Diseases 0.000 claims description 7
• 102000004305 alpha Adrenergic Receptors Human genes 0.000 claims description 7
• 108090000861 alpha Adrenergic Receptors Proteins 0.000 claims description 7
• 206010003119 arrhythmia Diseases 0.000 claims description 7
• 230000006793 arrhythmia Effects 0.000 claims description 7
• 239000000480 calcium channel blocker Substances 0.000 claims description 7
• 239000007789 gas Substances 0.000 claims description 7
• 230000000004 hemodynamic effect Effects 0.000 claims description 7
• 238000005259 measurement Methods 0.000 claims description 7
• PYLWMHQQBFSUBP-UHFFFAOYSA-N monofluorobenzene Chemical compound FC1=CC=CC=C1 PYLWMHQQBFSUBP-UHFFFAOYSA-N 0.000 claims description 7
• 230000002441 reversible effect Effects 0.000 claims description 7
• 230000008673 vomiting Effects 0.000 claims description 7
• WACNXHCZHTVBJM-UHFFFAOYSA-N 1,2,3,4,5-pentafluorobenzene Chemical compound FC1=CC(F)=C(F)C(F)=C1F WACNXHCZHTVBJM-UHFFFAOYSA-N 0.000 claims description 6
• 206010008479 Chest Pain Diseases 0.000 claims description 6
• 229940094659 Dopamine reuptake inhibitor Drugs 0.000 claims description 6
• 206010013954 Dysphoria Diseases 0.000 claims description 6
• 239000012190 activator Substances 0.000 claims description 6
• 229940121359 adenosine receptor antagonist Drugs 0.000 claims description 6
• 238000013019 agitation Methods 0.000 claims description 6
• 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims description 6
• RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 claims description 6
• 230000001149 cognitive effect Effects 0.000 claims description 6
• 230000034994 death Effects 0.000 claims description 6
• 231100000517 death Toxicity 0.000 claims description 6
• 208000002173 dizziness Diseases 0.000 claims description 6
• 239000000221 dopamine uptake inhibitor Substances 0.000 claims description 6
• 206010021654 increased appetite Diseases 0.000 claims description 6
• 238000007726 management method Methods 0.000 claims description 6
• 239000000296 purinergic P1 receptor antagonist Substances 0.000 claims description 6
• 238000007492 two-way ANOVA Methods 0.000 claims description 6
• DBGIVFWFUFKIQN-UHFFFAOYSA-N (+-)-Fenfluramine Chemical compound CCNC(C)CC1=CC=CC(C(F)(F)F)=C1 DBGIVFWFUFKIQN-UHFFFAOYSA-N 0.000 claims description 5
• OOBHFESNSZDWIU-GXSJLCMTSA-N (2s,3s)-3-methyl-2-phenylmorpholine Chemical compound C[C@@H]1NCCO[C@H]1C1=CC=CC=C1 OOBHFESNSZDWIU-GXSJLCMTSA-N 0.000 claims description 5
• GQIVTWIJJVAWQR-DANDVKJOSA-N (4r,4ar,7ar,12bs)-9-methoxy-3-methyl-1,2,4,4a,5,6,7a,13-octahydro-4,12-methanobenzofuro[3,2-e]isoquinoline-7-one;(2r,3r)-2,3-dihydroxybutanedioic acid;n-(4-hydroxyphenyl)acetamide Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O.CC(=O)NC1=CC=C(O)C=C1.C([C@H]1[C@H](N(CC[C@@]112)C)C3)CC(=O)[C@@H]1OC1=C2C3=CC=C1OC GQIVTWIJJVAWQR-DANDVKJOSA-N 0.000 claims description 5
• TVYLLZQTGLZFBW-ZBFHGGJFSA-N (R,R)-tramadol Chemical compound COC1=CC=CC([C@]2(O)[C@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-ZBFHGGJFSA-N 0.000 claims description 5
• PEBWOGPSYUIOBP-UHFFFAOYSA-N 1,2,4-trifluorobenzene Chemical compound FC1=CC=C(F)C(F)=C1 PEBWOGPSYUIOBP-UHFFFAOYSA-N 0.000 claims description 5
• SHXWCVYOXRDMCX-UHFFFAOYSA-N 3,4-methylenedioxymethamphetamine Chemical group CNC(C)CC1=CC=C2OCOC2=C1 SHXWCVYOXRDMCX-UHFFFAOYSA-N 0.000 claims description 5
• RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 claims description 5
• 208000031229 Cardiomyopathies Diseases 0.000 claims description 5
• 229940099362 Catechol O methyltransferase inhibitor Drugs 0.000 claims description 5
• 208000000059 Dyspnea Diseases 0.000 claims description 5
• 206010013975 Dyspnoeas Diseases 0.000 claims description 5
• 206010016059 Facial pain Diseases 0.000 claims description 5
• 206010019233 Headaches Diseases 0.000 claims description 5
• GVGLGOZIDCSQPN-PVHGPHFFSA-N Heroin Chemical compound O([C@H]1[C@H](C=C[C@H]23)OC(C)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4OC(C)=O GVGLGOZIDCSQPN-PVHGPHFFSA-N 0.000 claims description 5
• YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 claims description 5
• 229940086616 Monoamine oxidase B inhibitor Drugs 0.000 claims description 5
• 229940121948 Muscarinic receptor antagonist Drugs 0.000 claims description 5
• 206010028735 Nasal congestion Diseases 0.000 claims description 5
• 108010040718 Neurokinin-1 Receptors Proteins 0.000 claims description 5
• QVDSEJDULKLHCG-UHFFFAOYSA-N Psilocybine Natural products C1=CC(OP(O)(O)=O)=C2C(CCN(C)C)=CNC2=C1 QVDSEJDULKLHCG-UHFFFAOYSA-N 0.000 claims description 5
• 102100037346 Substance-P receptor Human genes 0.000 claims description 5
• 208000012886 Vertigo Diseases 0.000 claims description 5
• 230000003444 anaesthetic effect Effects 0.000 claims description 5
• 230000000202 analgesic effect Effects 0.000 claims description 5
• 239000002249 anxiolytic agent Substances 0.000 claims description 5
• 230000000949 anxiolytic effect Effects 0.000 claims description 5
• 238000013459 approach Methods 0.000 claims description 5
• 229930003827 cannabinoid Natural products 0.000 claims description 5
• 239000003557 cannabinoid Substances 0.000 claims description 5
• 239000003543 catechol methyltransferase inhibitor Substances 0.000 claims description 5
• 239000000812 cholinergic antagonist Substances 0.000 claims description 5
• 229960000632 dexamfetamine Drugs 0.000 claims description 5
• 229960002069 diamorphine Drugs 0.000 claims description 5
• XYYVYLMBEZUESM-UHFFFAOYSA-N dihydrocodeine Natural products C1C(N(CCC234)C)C2C=CC(=O)C3OC2=C4C1=CC=C2OC XYYVYLMBEZUESM-UHFFFAOYSA-N 0.000 claims description 5
• 208000001780 epistaxis Diseases 0.000 claims description 5
• 229960001582 fenfluramine Drugs 0.000 claims description 5
• 230000006870 function Effects 0.000 claims description 5
• 231100001261 hazardous Toxicity 0.000 claims description 5
• 231100000869 headache Toxicity 0.000 claims description 5
• 235000003642 hunger Nutrition 0.000 claims description 5
• LLPOLZWFYMWNKH-CMKMFDCUSA-N hydrocodone Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)CC(=O)[C@@H]1OC1=C2C3=CC=C1OC LLPOLZWFYMWNKH-CMKMFDCUSA-N 0.000 claims description 5
• 229960000240 hydrocodone Drugs 0.000 claims description 5
• OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 claims description 5
• 230000000147 hypnotic effect Effects 0.000 claims description 5
• 229960003299 ketamine Drugs 0.000 claims description 5
• 230000033001 locomotion Effects 0.000 claims description 5
• 229940061871 lorcet Drugs 0.000 claims description 5
• 229940089568 lortab Drugs 0.000 claims description 5
• 230000015654 memory Effects 0.000 claims description 5
• MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 claims description 5
• 229960001252 methamphetamine Drugs 0.000 claims description 5
• 208000010125 myocardial infarction Diseases 0.000 claims description 5
• 239000003158 myorelaxant agent Substances 0.000 claims description 5
• 239000000820 nonprescription drug Substances 0.000 claims description 5
• 229960002085 oxycodone Drugs 0.000 claims description 5
• 230000008058 pain sensation Effects 0.000 claims description 5
• 229960000761 pemoline Drugs 0.000 claims description 5
• NRNCYVBFPDDJNE-UHFFFAOYSA-N pemoline Chemical compound O1C(N)=NC(=O)C1C1=CC=CC=C1 NRNCYVBFPDDJNE-UHFFFAOYSA-N 0.000 claims description 5
• 229960001412 pentobarbital Drugs 0.000 claims description 5
• 229940011043 percocet Drugs 0.000 claims description 5
• 229960003209 phenmetrazine Drugs 0.000 claims description 5
• 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 5
• QKTAAWLCLHMUTJ-UHFFFAOYSA-N psilocybin Chemical compound C1C=CC(OP(O)(O)=O)=C2C(CCN(C)C)=CN=C21 QKTAAWLCLHMUTJ-UHFFFAOYSA-N 0.000 claims description 5
• 239000000932 sedative agent Substances 0.000 claims description 5
• 230000001624 sedative effect Effects 0.000 claims description 5
• 208000013220 shortness of breath Diseases 0.000 claims description 5
• 239000000725 suspension Substances 0.000 claims description 5
• 229960004380 tramadol Drugs 0.000 claims description 5
• TVYLLZQTGLZFBW-GOEBONIOSA-N tramadol Natural products COC1=CC=CC([C@@]2(O)[C@@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-GOEBONIOSA-N 0.000 claims description 5
• 229940125725 tranquilizer Drugs 0.000 claims description 5
• 239000003204 tranquilizing agent Substances 0.000 claims description 5
• 230000002936 tranquilizing effect Effects 0.000 claims description 5
• LLPOLZWFYMWNKH-UHFFFAOYSA-N trans-dihydrocodeinone Natural products C1C(N(CCC234)C)C2CCC(=O)C3OC2=C4C1=CC=C2OC LLPOLZWFYMWNKH-UHFFFAOYSA-N 0.000 claims description 5
• 230000001052 transient effect Effects 0.000 claims description 5
• 231100000889 vertigo Toxicity 0.000 claims description 5
• 229940000146 vicodin Drugs 0.000 claims description 5
• SXPRVMIZFRCAGC-UHFFFAOYSA-N 1,2,3,4,5-pentafluoro-6-methylbenzene Chemical compound CC1=C(F)C(F)=C(F)C(F)=C1F SXPRVMIZFRCAGC-UHFFFAOYSA-N 0.000 claims description 4
• SJZRECIVHVDYJC-UHFFFAOYSA-M 4-hydroxybutyrate Chemical compound OCCCC([O-])=O SJZRECIVHVDYJC-UHFFFAOYSA-M 0.000 claims description 4
• 229940123702 Adenosine A2a receptor antagonist Drugs 0.000 claims description 4
• 206010020772 Hypertension Diseases 0.000 claims description 4
• WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 claims description 4
• WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 claims description 4
• 208000006550 Mydriasis Diseases 0.000 claims description 4
• 206010052437 Nasal discomfort Diseases 0.000 claims description 4
• 206010033557 Palpitations Diseases 0.000 claims description 4
• GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 claims description 4
• AFCGFAGUEYAMAO-UHFFFAOYSA-N acamprosate Chemical compound CC(=O)NCCCS(O)(=O)=O AFCGFAGUEYAMAO-UHFFFAOYSA-N 0.000 claims description 4
• 229960004047 acamprosate Drugs 0.000 claims description 4
• 239000002467 adenosine A2a receptor antagonist Substances 0.000 claims description 4
• 230000001387 anti-histamine Effects 0.000 claims description 4
• 239000000739 antihistaminic agent Substances 0.000 claims description 4
• 229940049706 benzodiazepine Drugs 0.000 claims description 4
• 206010006451 bronchitis Diseases 0.000 claims description 4
• 238000009225 cognitive behavioral therapy Methods 0.000 claims description 4
• 230000003111 delayed effect Effects 0.000 claims description 4
• 238000001647 drug administration Methods 0.000 claims description 4
• 230000001771 impaired effect Effects 0.000 claims description 4
• 238000001990 intravenous administration Methods 0.000 claims description 4
• 229960004502 levodopa Drugs 0.000 claims description 4
• 229960000299 mazindol Drugs 0.000 claims description 4
• 230000003340 mental effect Effects 0.000 claims description 4
• 238000012544 monitoring process Methods 0.000 claims description 4
• 238000007920 subcutaneous administration Methods 0.000 claims description 4
• 239000000758 substrate Substances 0.000 claims description 4
• 239000005541 ACE inhibitor Substances 0.000 claims description 3
• 229940123041 Dopamine b hydroxylase inhibitor Drugs 0.000 claims description 3
• LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 claims description 3
• 206010037660 Pyrexia Diseases 0.000 claims description 3
• 206010044565 Tremor Diseases 0.000 claims description 3
• 125000003158 alcohol group Chemical group 0.000 claims description 3
• 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 claims description 3
• 230000004872 arterial blood pressure Effects 0.000 claims description 3
• 239000002585 base Substances 0.000 claims description 3
• 210000004556 brain Anatomy 0.000 claims description 3
• 229960001948 caffeine Drugs 0.000 claims description 3
• VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 claims description 3
• 230000001055 chewing effect Effects 0.000 claims description 3
• XXEPPPIWZFICOJ-UHFFFAOYSA-N diethylpropion Chemical compound CCN(CC)C(C)C(=O)C1=CC=CC=C1 XXEPPPIWZFICOJ-UHFFFAOYSA-N 0.000 claims description 3
• 229960004890 diethylpropion Drugs 0.000 claims description 3
• 210000003191 femoral vein Anatomy 0.000 claims description 3
• 230000001631 hypertensive effect Effects 0.000 claims description 3
• 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims description 3
• 230000000144 pharmacologic effect Effects 0.000 claims description 3
• 230000035882 stress Effects 0.000 claims description 3
• 238000011706 wistar kyoto rat Methods 0.000 claims description 3
• 230000000747 cardiac effect Effects 0.000 claims description 2
• 239000012153 distilled water Substances 0.000 claims description 2
• 210000001105 femoral artery Anatomy 0.000 claims description 2
• BCQZXOMGPXTTIC-UHFFFAOYSA-N halothane Chemical compound FC(F)(F)C(Cl)Br BCQZXOMGPXTTIC-UHFFFAOYSA-N 0.000 claims description 2
• 229960003132 halothane Drugs 0.000 claims description 2
• 238000002347 injection Methods 0.000 claims description 2
• 239000007924 injection Substances 0.000 claims description 2
• 230000005923 long-lasting effect Effects 0.000 claims description 2
• 230000007246 mechanism Effects 0.000 claims description 2
• 239000000843 powder Substances 0.000 claims description 2
• 238000002360 preparation method Methods 0.000 claims description 2
• 238000011084 recovery Methods 0.000 claims description 2
• 230000000717 retained effect Effects 0.000 claims description 2
• 230000035945 sensitivity Effects 0.000 claims description 2
• 229910001220 stainless steel Inorganic materials 0.000 claims description 2
• 239000010935 stainless steel Substances 0.000 claims description 2
• 229930000680 A04AD01 - Scopolamine Natural products 0.000 claims 50
• STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 claims 50
• STECJAGHUSJQJN-UHFFFAOYSA-N N-Methyl-scopolamin Natural products C1C(C2C3O2)N(C)C3CC1OC(=O)C(CO)C1=CC=CC=C1 STECJAGHUSJQJN-UHFFFAOYSA-N 0.000 claims 50
• STECJAGHUSJQJN-FWXGHANASA-N scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 claims 50
• 229960002646 scopolamine Drugs 0.000 claims 50
• PIJVFDBKTWXHHD-UHFFFAOYSA-N Physostigmine Natural products C12=CC(OC(=O)NC)=CC=C2N(C)C2C1(C)CCN2C PIJVFDBKTWXHHD-UHFFFAOYSA-N 0.000 claims 37
• 229960001697 physostigmine Drugs 0.000 claims 37
• PIJVFDBKTWXHHD-HIFRSBDPSA-N physostigmine Chemical compound C12=CC(OC(=O)NC)=CC=C2N(C)[C@@H]2[C@@]1(C)CCN2C PIJVFDBKTWXHHD-HIFRSBDPSA-N 0.000 claims 37
• 108010061435 Enalapril Proteins 0.000 claims 34
• GBXSMTUPTTWBMN-XIRDDKMYSA-N enalapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 GBXSMTUPTTWBMN-XIRDDKMYSA-N 0.000 claims 34
• 229960000873 enalapril Drugs 0.000 claims 34
• 235000013305 food Nutrition 0.000 claims 18
• 230000001934 delay Effects 0.000 claims 13
• 238000011260 co-administration Methods 0.000 claims 11
• 238000012937 correction Methods 0.000 claims 11
• 230000037023 motor activity Effects 0.000 claims 10
• OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 claims 9
• 229960004373 acetylcholine Drugs 0.000 claims 9
• 239000002968 autonomic agent Substances 0.000 claims 8
• JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 claims 7
• 229940039009 isoproterenol Drugs 0.000 claims 7
• 241000699670 Mus sp. Species 0.000 claims 6
• LACQPOBCQQPVIT-SEYKEWMNSA-N scopolamine hydrobromide trihydrate Chemical compound O.O.O.Br.C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 LACQPOBCQQPVIT-SEYKEWMNSA-N 0.000 claims 6
• 238000001061 Dunnett's test Methods 0.000 claims 4
• 206010020880 Hypertrophy Diseases 0.000 claims 4
• 210000001198 duodenum Anatomy 0.000 claims 4
• 238000007619 statistical method Methods 0.000 claims 4
• 206010002091 Anaesthesia Diseases 0.000 claims 3
• QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 claims 3
• 208000001871 Tachycardia Diseases 0.000 claims 3
• 230000037005 anaesthesia Effects 0.000 claims 3
• 230000035487 diastolic blood pressure Effects 0.000 claims 3
• 230000006742 locomotor activity Effects 0.000 claims 3
• 238000005192 partition Methods 0.000 claims 3
• 231100000161 signs of toxicity Toxicity 0.000 claims 3
• 230000035488 systolic blood pressure Effects 0.000 claims 3
• 101710129690 Angiotensin-converting enzyme inhibitor Proteins 0.000 claims 2
• 101710086378 Bradykinin-potentiating and C-type natriuretic peptides Proteins 0.000 claims 2
• 108090000312 Calcium Channels Proteins 0.000 claims 2
• 102000003922 Calcium Channels Human genes 0.000 claims 2
• PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 claims 2
• 229920005439 Perspex® Polymers 0.000 claims 2
• 239000004698 Polyethylene Substances 0.000 claims 2
• 238000000692 Student's t-test Methods 0.000 claims 2
• 210000001015 abdomen Anatomy 0.000 claims 2
• 230000003187 abdominal effect Effects 0.000 claims 2
• 238000009530 blood pressure measurement Methods 0.000 claims 2
• 230000036760 body temperature Effects 0.000 claims 2
• 230000008859 change Effects 0.000 claims 2
• QLTXKCWMEZIHBJ-PJGJYSAQSA-N dizocilpine maleate Chemical compound OC(=O)\C=C/C(O)=O.C12=CC=CC=C2[C@]2(C)C3=CC=CC=C3C[C@H]1N2 QLTXKCWMEZIHBJ-PJGJYSAQSA-N 0.000 claims 2
• 238000013100 final test Methods 0.000 claims 2
• 238000005286 illumination Methods 0.000 claims 2
• 239000007943 implant Substances 0.000 claims 2
• 229960002725 isoflurane Drugs 0.000 claims 2
• 206010027175 memory impairment Diseases 0.000 claims 2
• 238000012986 modification Methods 0.000 claims 2
• 230000004048 modification Effects 0.000 claims 2
• 229920000573 polyethylene Polymers 0.000 claims 2
• 239000004926 polymethyl methacrylate Substances 0.000 claims 2
• 230000002269 spontaneous effect Effects 0.000 claims 2
• 238000013222 sprague-dawley male rat Methods 0.000 claims 2
• 238000012353 t test Methods 0.000 claims 2
• 230000006794 tachycardia Effects 0.000 claims 2
• 231100000331 toxic Toxicity 0.000 claims 2
• 230000002588 toxic effect Effects 0.000 claims 2
• 238000005303 weighing Methods 0.000 claims 2
• 230000003936 working memory Effects 0.000 claims 2
• 206010003591 Ataxia Diseases 0.000 claims 1
• 206010007572 Cardiac hypertrophy Diseases 0.000 claims 1
• 208000006029 Cardiomegaly Diseases 0.000 claims 1
• 241000218645 Cedrus Species 0.000 claims 1
• 206010011703 Cyanosis Diseases 0.000 claims 1
• 206010011906 Death Diseases 0.000 claims 1
• 206010052804 Drug tolerance Diseases 0.000 claims 1
• 108010066671 Enalaprilat Proteins 0.000 claims 1
• 241001331845 Equus asinus x caballus Species 0.000 claims 1
• 206010021033 Hypomenorrhoea Diseases 0.000 claims 1
• 238000012313 Kruskal-Wallis test Methods 0.000 claims 1
• STECJAGHUSJQJN-USLFZFAMSA-N LSM-4015 Chemical compound C1([C@@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-USLFZFAMSA-N 0.000 claims 1
• 208000007177 Left Ventricular Hypertrophy Diseases 0.000 claims 1
• 102000010909 Monoamine Oxidase Human genes 0.000 claims 1
• 108010062431 Monoamine oxidase Proteins 0.000 claims 1
• 241000220317 Rosa Species 0.000 claims 1
• 206010039424 Salivary hypersecretion Diseases 0.000 claims 1
• 108010052164 Sodium Channels Proteins 0.000 claims 1
• 102000018674 Sodium Channels Human genes 0.000 claims 1
• YYBNDIVPHIWTPK-KYJQVDHRSA-N [(3as,8bs)-3,4,8b-trimethyl-1,2,3,3a-tetrahydropyrrolo[2,3-b]indol-3-ium-7-yl] n-methylcarbamate;sulfate Chemical compound [O-]S([O-])(=O)=O.C12=CC(OC(=O)NC)=CC=C2N(C)[C@@H]2[C@@]1(C)CC[NH+]2C.C12=CC(OC(=O)NC)=CC=C2N(C)[C@@H]2[C@@]1(C)CC[NH+]2C YYBNDIVPHIWTPK-KYJQVDHRSA-N 0.000 claims 1
• 231100000215 acute (single dose) toxicity testing Toxicity 0.000 claims 1
• 230000006978 adaptation Effects 0.000 claims 1
• 210000000702 aorta abdominal Anatomy 0.000 claims 1
• 210000002376 aorta thoracic Anatomy 0.000 claims 1
• 239000007864 aqueous solution Substances 0.000 claims 1
• QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 1
• 230000036471 bradycardia Effects 0.000 claims 1
• 208000006218 bradycardia Diseases 0.000 claims 1
• PIQVDUKEQYOJNR-VZXSFKIWSA-N cocaine hydrochloride Chemical compound [Cl-].O([C@H]1C[C@@H]2CC[C@@H]([NH+]2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 PIQVDUKEQYOJNR-VZXSFKIWSA-N 0.000 claims 1
• 229960003771 cocaine hydrochloride Drugs 0.000 claims 1
• 230000036461 convulsion Effects 0.000 claims 1
• 238000007405 data analysis Methods 0.000 claims 1
• 238000013480 data collection Methods 0.000 claims 1
• 239000008367 deionised water Substances 0.000 claims 1
• 229910021641 deionized water Inorganic materials 0.000 claims 1
• 229960003529 diazepam Drugs 0.000 claims 1
• AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 claims 1
• 238000003255 drug test Methods 0.000 claims 1
• OYFJQPXVCSSHAI-QFPUQLAESA-N enalapril maleate Chemical compound OC(=O)\C=C/C(O)=O.C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 OYFJQPXVCSSHAI-QFPUQLAESA-N 0.000 claims 1
• 230000026781 habituation Effects 0.000 claims 1
• 210000003128 head Anatomy 0.000 claims 1
• 238000007912 intraperitoneal administration Methods 0.000 claims 1
• 238000002350 laparotomy Methods 0.000 claims 1
• 230000003137 locomotive effect Effects 0.000 claims 1
• 230000014759 maintenance of location Effects 0.000 claims 1
• 230000006883 memory enhancing effect Effects 0.000 claims 1
• 229910052751 metal Inorganic materials 0.000 claims 1
• 239000002184 metal Substances 0.000 claims 1
• 230000008450 motivation Effects 0.000 claims 1
• 230000001095 motoneuron effect Effects 0.000 claims 1
• 239000001301 oxygen Substances 0.000 claims 1
• 229910052760 oxygen Inorganic materials 0.000 claims 1
• 229960002275 pentobarbital sodium Drugs 0.000 claims 1
• 230000001766 physiological effect Effects 0.000 claims 1
• 230000003334 potential effect Effects 0.000 claims 1
• 238000002203 pretreatment Methods 0.000 claims 1
• 210000001187 pylorus Anatomy 0.000 claims 1
• 238000011160 research Methods 0.000 claims 1
• 208000026451 salivation Diseases 0.000 claims 1
• 238000011012 sanitization Methods 0.000 claims 1
• 230000006403 short-term memory Effects 0.000 claims 1
• 238000000528 statistical test Methods 0.000 claims 1
• 239000008223 sterile water Substances 0.000 claims 1
• 238000010254 subcutaneous injection Methods 0.000 claims 1
• 230000009897 systematic effect Effects 0.000 claims 1
• 229940099270 vasotec Drugs 0.000 claims 1
• 230000003519 ventilatory effect Effects 0.000 claims 1
• 230000004580 weight loss Effects 0.000 claims 1
• AUZONCFQVSMFAP-UHFFFAOYSA-N disulfiram Chemical compound CCN(CC)C(=S)SSC(=S)N(CC)CC AUZONCFQVSMFAP-UHFFFAOYSA-N 0.000 description 58
• 239000012071 phase Substances 0.000 description 41
• 108700006189 dopamine beta hydroxylase deficiency Proteins 0.000 description 38
• 231100000736 substance abuse Toxicity 0.000 description 35
• OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 34
• 229960002563 disulfiram Drugs 0.000 description 29
• IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 24
• 239000000902 placebo Substances 0.000 description 22
• 229940068196 placebo Drugs 0.000 description 22
• 229940088598 enzyme Drugs 0.000 description 19
• 208000028017 Psychotic disease Diseases 0.000 description 17
• 208000019022 Mood disease Diseases 0.000 description 14
• 238000006243 chemical reaction Methods 0.000 description 14
• 230000003389 potentiating effect Effects 0.000 description 14
• 208000026251 Opioid-Related disease Diseases 0.000 description 13
• FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 description 12
• 229960000623 carbamazepine Drugs 0.000 description 12
• DZGWFCGJZKJUFP-UHFFFAOYSA-N tyramine Chemical compound NCCC1=CC=C(O)C=C1 DZGWFCGJZKJUFP-UHFFFAOYSA-N 0.000 description 12
• 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 11
• 238000003556 assay Methods 0.000 description 11
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 11
• 230000002526 effect on cardiovascular system Effects 0.000 description 11
• 230000035987 intoxication Effects 0.000 description 11
• 231100000566 intoxication Toxicity 0.000 description 11
• 230000002889 sympathetic effect Effects 0.000 description 11
• XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 10
• VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 10
• OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 10
• 229960001058 bupropion Drugs 0.000 description 10
• SNPPWIUOZRMYNY-UHFFFAOYSA-N bupropion Chemical compound CC(C)(C)NC(C)C(=O)C1=CC=CC(Cl)=C1 SNPPWIUOZRMYNY-UHFFFAOYSA-N 0.000 description 10
• 201000005040 opiate dependence Diseases 0.000 description 10
• 241000283690 Bos taurus Species 0.000 description 9
• RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 9
• 208000004547 Hallucinations Diseases 0.000 description 9
• KJADKKWYZYXHBB-XBWDGYHZSA-N Topiramic acid Chemical compound C1O[C@@]2(COS(N)(=O)=O)OC(C)(C)O[C@H]2[C@@H]2OC(C)(C)O[C@@H]21 KJADKKWYZYXHBB-XBWDGYHZSA-N 0.000 description 9
• 230000002401 inhibitory effect Effects 0.000 description 9
• 230000005764 inhibitory process Effects 0.000 description 9
• PYZRQGJRPPTADH-UHFFFAOYSA-N lamotrigine Chemical compound NC1=NC(N)=NN=C1C1=CC=CC(Cl)=C1Cl PYZRQGJRPPTADH-UHFFFAOYSA-N 0.000 description 9
• 229960001848 lamotrigine Drugs 0.000 description 9
• 239000007788 liquid Substances 0.000 description 9
• 239000000546 pharmaceutical excipient Substances 0.000 description 9
• AEQFSUDEHCCHBT-UHFFFAOYSA-M sodium valproate Chemical compound [Na+].CCCC(C([O-])=O)CCC AEQFSUDEHCCHBT-UHFFFAOYSA-M 0.000 description 9
• 239000007787 solid Substances 0.000 description 9
• 229960004394 topiramate Drugs 0.000 description 9
• 210000002700 urine Anatomy 0.000 description 9
• 229940102566 valproate Drugs 0.000 description 9
• CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 8
• IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
• 206010057852 Nicotine dependence Diseases 0.000 description 8
• OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 8
• 208000025569 Tobacco Use disease Diseases 0.000 description 8
• 239000002253 acid Substances 0.000 description 8
• 150000001412 amines Chemical class 0.000 description 8
• 230000018109 developmental process Effects 0.000 description 8
• 208000035475 disorder Diseases 0.000 description 8
• 239000011541 reaction mixture Substances 0.000 description 8
• 239000000523 sample Substances 0.000 description 8
• 239000002904 solvent Substances 0.000 description 8
• 206010010219 Compulsions Diseases 0.000 description 7
• 206010012218 Delirium Diseases 0.000 description 7
• 206010012239 Delusion Diseases 0.000 description 7
• 230000016571 aggressive behavior Effects 0.000 description 7
• 231100000868 delusion Toxicity 0.000 description 7
• 230000009429 distress Effects 0.000 description 7
• 239000000047 product Substances 0.000 description 7
• 238000001228 spectrum Methods 0.000 description 7
• CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
• 108090000371 Esterases Proteins 0.000 description 6
• 206010019280 Heart failures Diseases 0.000 description 6
• HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
• 238000011292 agonist therapy Methods 0.000 description 6
• 230000027455 binding Effects 0.000 description 6
• 238000009739 binding Methods 0.000 description 6
• 239000002775 capsule Substances 0.000 description 6
• 238000001802 infusion Methods 0.000 description 6
• VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
• 229960001816 oxcarbazepine Drugs 0.000 description 6
• CTRLABGOLIVAIY-UHFFFAOYSA-N oxcarbazepine Chemical compound C1C(=O)C2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 CTRLABGOLIVAIY-UHFFFAOYSA-N 0.000 description 6
• WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 6
• VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 6
• 208000020016 psychiatric disease Diseases 0.000 description 6
• 229960003732 tyramine Drugs 0.000 description 6
• KPYSYYIEGFHWSV-UHFFFAOYSA-N Baclofen Chemical compound OC(=O)CC(CN)C1=CC=C(Cl)C=C1 KPYSYYIEGFHWSV-UHFFFAOYSA-N 0.000 description 5
• 239000002126 C01EB10 - Adenosine Substances 0.000 description 5
• 206010007559 Cardiac failure congestive Diseases 0.000 description 5
• 229960005305 adenosine Drugs 0.000 description 5
• 229960000794 baclofen Drugs 0.000 description 5
• 238000004296 chiral HPLC Methods 0.000 description 5
• 235000019439 ethyl acetate Nutrition 0.000 description 5
• 238000001704 evaporation Methods 0.000 description 5
• 238000004128 high performance liquid chromatography Methods 0.000 description 5
• 238000000338 in vitro Methods 0.000 description 5
• DQCKKXVULJGBQN-XFWGSAIBSA-N naltrexone Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CCC5=O)O)CC1)O)CC1CC1 DQCKKXVULJGBQN-XFWGSAIBSA-N 0.000 description 5
• 229960003086 naltrexone Drugs 0.000 description 5
• 150000002825 nitriles Chemical class 0.000 description 5
• 229960001576 octopamine Drugs 0.000 description 5
• 230000036470 plasma concentration Effects 0.000 description 5
• 210000002254 renal artery Anatomy 0.000 description 5
• 238000012216 screening Methods 0.000 description 5
• 229960001918 tiagabine Drugs 0.000 description 5
• PBJUNZJWGZTSKL-MRXNPFEDSA-N tiagabine Chemical compound C1=CSC(C(=CCCN2C[C@@H](CCC2)C(O)=O)C2=C(C=CS2)C)=C1C PBJUNZJWGZTSKL-MRXNPFEDSA-N 0.000 description 5
• 229960005318 vigabatrin Drugs 0.000 description 5
• PJDFLNIOAUIZSL-UHFFFAOYSA-N vigabatrin Chemical compound C=CC(N)CCC(O)=O PJDFLNIOAUIZSL-UHFFFAOYSA-N 0.000 description 5
• RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 description 4
• QHGUCRYDKWKLMG-QMMMGPOBSA-N (R)-octopamine Chemical compound NC[C@H](O)C1=CC=C(O)C=C1 QHGUCRYDKWKLMG-QMMMGPOBSA-N 0.000 description 4
• QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 4
• XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 4
• 102000016938 Catalase Human genes 0.000 description 4
• 108010053835 Catalase Proteins 0.000 description 4
• HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
• HCYAFALTSJYZDH-UHFFFAOYSA-N Desimpramine Chemical compound C1CC2=CC=CC=C2N(CCCNC)C2=CC=CC=C21 HCYAFALTSJYZDH-UHFFFAOYSA-N 0.000 description 4
• 208000010201 Exanthema Diseases 0.000 description 4
• VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
• WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 4
• QHGUCRYDKWKLMG-MRVPVSSYSA-N Octopamine Natural products NC[C@@H](O)C1=CC=C(O)C=C1 QHGUCRYDKWKLMG-MRVPVSSYSA-N 0.000 description 4
• CXOFVDLJLONNDW-UHFFFAOYSA-N Phenytoin Chemical compound N1C(=O)NC(=O)C1(C=1C=CC=CC=1)C1=CC=CC=C1 CXOFVDLJLONNDW-UHFFFAOYSA-N 0.000 description 4
• PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 4
• 230000004913 activation Effects 0.000 description 4
• 230000002411 adverse Effects 0.000 description 4
• DKNWSYNQZKUICI-UHFFFAOYSA-N amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 description 4
• 229960003805 amantadine Drugs 0.000 description 4
• 230000001174 ascending effect Effects 0.000 description 4
• 229940072107 ascorbate Drugs 0.000 description 4
• 235000010323 ascorbic acid Nutrition 0.000 description 4
• 239000011668 ascorbic acid Substances 0.000 description 4
• 150000001540 azides Chemical class 0.000 description 4
• 230000008901 benefit Effects 0.000 description 4
• 239000012267 brine Substances 0.000 description 4
• OZVBMTJYIDMWIL-AYFBDAFISA-N bromocriptine Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@]2(C(=O)N3[C@H](C(N4CCC[C@H]4[C@]3(O)O2)=O)CC(C)C)C(C)C)C2)=C3C2=C(Br)NC3=C1 OZVBMTJYIDMWIL-AYFBDAFISA-N 0.000 description 4
• 229960002802 bromocriptine Drugs 0.000 description 4
• 229940105657 catalase Drugs 0.000 description 4
• 238000004587 chromatography analysis Methods 0.000 description 4
• DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 4
• 229960003914 desipramine Drugs 0.000 description 4
• 230000003292 diminished effect Effects 0.000 description 4
• 201000005884 exanthem Diseases 0.000 description 4
• 229960002464 fluoxetine Drugs 0.000 description 4
• 229960000647 gepirone Drugs 0.000 description 4
• QOIGKGMMAGJZNZ-UHFFFAOYSA-N gepirone Chemical compound O=C1CC(C)(C)CC(=O)N1CCCCN1CCN(C=2N=CC=CN=2)CC1 QOIGKGMMAGJZNZ-UHFFFAOYSA-N 0.000 description 4
• RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 4
• RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 4
• 229960004801 imipramine Drugs 0.000 description 4
• BCGWQEUPMDMJNV-UHFFFAOYSA-N imipramine Chemical compound C1CC2=CC=CC=C2N(CCCN(C)C)C2=CC=CC=C21 BCGWQEUPMDMJNV-UHFFFAOYSA-N 0.000 description 4
• 238000001727 in vivo Methods 0.000 description 4
• 229910052744 lithium Inorganic materials 0.000 description 4
• 230000036651 mood Effects 0.000 description 4
• 229910052757 nitrogen Inorganic materials 0.000 description 4
• 229940078552 o-xylene Drugs 0.000 description 4
• 239000003921 oil Substances 0.000 description 4
• 235000019198 oils Nutrition 0.000 description 4
• 229960004851 pergolide Drugs 0.000 description 4
• YEHCICAEULNIGD-MZMPZRCHSA-N pergolide Chemical compound C1=CC([C@H]2C[C@@H](CSC)CN([C@@H]2C2)CCC)=C3C2=CNC3=C1 YEHCICAEULNIGD-MZMPZRCHSA-N 0.000 description 4
• 229960002036 phenytoin Drugs 0.000 description 4
• AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 4
• 235000021251 pulses Nutrition 0.000 description 4
• 206010037844 rash Diseases 0.000 description 4
• 238000010992 reflux Methods 0.000 description 4
• 229950009626 ritanserin Drugs 0.000 description 4
• JUQLTPCYUFPYKE-UHFFFAOYSA-N ritanserin Chemical compound CC=1N=C2SC=CN2C(=O)C=1CCN(CC1)CCC1=C(C=1C=CC(F)=CC=1)C1=CC=C(F)C=C1 JUQLTPCYUFPYKE-UHFFFAOYSA-N 0.000 description 4
• 239000000377 silicon dioxide Substances 0.000 description 4
• HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 4
• 238000003756 stirring Methods 0.000 description 4
• 210000002820 sympathetic nervous system Anatomy 0.000 description 4
• 230000001225 therapeutic effect Effects 0.000 description 4
• 238000002560 therapeutic procedure Methods 0.000 description 4
• 230000004797 therapeutic response Effects 0.000 description 4
• 210000001685 thyroid gland Anatomy 0.000 description 4
• VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 4
• AHOUBRCZNHFOSL-YOEHRIQHSA-N (+)-Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 description 3
• WSEQXVZVJXJVFP-HXUWFJFHSA-N (R)-citalopram Chemical compound C1([C@@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WSEQXVZVJXJVFP-HXUWFJFHSA-N 0.000 description 3
• ZEUITGRIYCTCEM-KRWDZBQOSA-N (S)-duloxetine Chemical compound C1([C@@H](OC=2C3=CC=CC=C3C=CC=2)CCNC)=CC=CS1 ZEUITGRIYCTCEM-KRWDZBQOSA-N 0.000 description 3
• 239000003477 4 aminobutyric acid receptor stimulating agent Substances 0.000 description 3
• 208000007848 Alcoholism Diseases 0.000 description 3
• 102000005369 Aldehyde Dehydrogenase Human genes 0.000 description 3
• 108020002663 Aldehyde Dehydrogenase Proteins 0.000 description 3
• 108700028369 Alleles Proteins 0.000 description 3
• 208000029197 Amphetamine-Related disease Diseases 0.000 description 3
• CEUORZQYGODEFX-UHFFFAOYSA-N Aripirazole Chemical compound ClC1=CC=CC(N2CCN(CCCCOC=3C=C4NC(=O)CCC4=CC=3)CC2)=C1Cl CEUORZQYGODEFX-UHFFFAOYSA-N 0.000 description 3
• CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 3
• GJSURZIOUXUGAL-UHFFFAOYSA-N Clonidine Chemical compound ClC1=CC=CC(Cl)=C1NC1=NCCN1 GJSURZIOUXUGAL-UHFFFAOYSA-N 0.000 description 3
• 206010012289 Dementia Diseases 0.000 description 3
• 206010012335 Dependence Diseases 0.000 description 3
• VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 3
• PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
• 102000004108 Neurotransmitter Receptors Human genes 0.000 description 3
• 108090000590 Neurotransmitter Receptors Proteins 0.000 description 3
• PHVGLTMQBUFIQQ-UHFFFAOYSA-N Nortryptiline Chemical compound C1CC2=CC=CC=C2C(=CCCNC)C2=CC=CC=C21 PHVGLTMQBUFIQQ-UHFFFAOYSA-N 0.000 description 3
• AHOUBRCZNHFOSL-UHFFFAOYSA-N Paroxetine hydrochloride Natural products C1=CC(F)=CC=C1C1C(COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-UHFFFAOYSA-N 0.000 description 3
• DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
• 208000001431 Psychomotor Agitation Diseases 0.000 description 3
• 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 3
• 239000000443 aerosol Substances 0.000 description 3
• 229960000836 amitriptyline Drugs 0.000 description 3
• KRMDCWKBEZIMAB-UHFFFAOYSA-N amitriptyline Chemical compound C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KRMDCWKBEZIMAB-UHFFFAOYSA-N 0.000 description 3
• 229960002519 amoxapine Drugs 0.000 description 3
• QWGDMFLQWFTERH-UHFFFAOYSA-N amoxapine Chemical compound C12=CC(Cl)=CC=C2OC2=CC=CC=C2N=C1N1CCNCC1 QWGDMFLQWFTERH-UHFFFAOYSA-N 0.000 description 3
• 229960004372 aripiprazole Drugs 0.000 description 3
• 210000001367 artery Anatomy 0.000 description 3
• 229960002430 atomoxetine Drugs 0.000 description 3
• VHGCDTVCOLNTBX-QGZVFWFLSA-N atomoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=CC=C1C VHGCDTVCOLNTBX-QGZVFWFLSA-N 0.000 description 3
• 230000006399 behavior Effects 0.000 description 3
• RMRJXGBAOAMLHD-IHFGGWKQSA-N buprenorphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)CN2CC1CC1 RMRJXGBAOAMLHD-IHFGGWKQSA-N 0.000 description 3
• 229960001736 buprenorphine Drugs 0.000 description 3
• QTAOMKOIBXZKND-PPHPATTJSA-N carbidopa Chemical compound O.NN[C@@](C(O)=O)(C)CC1=CC=C(O)C(O)=C1 QTAOMKOIBXZKND-PPHPATTJSA-N 0.000 description 3
• 229960004205 carbidopa Drugs 0.000 description 3
• 210000004027 cell Anatomy 0.000 description 3
• 229960001653 citalopram Drugs 0.000 description 3
• 229960002896 clonidine Drugs 0.000 description 3
• 210000003748 coronary sinus Anatomy 0.000 description 3
• 238000013461 design Methods 0.000 description 3
• 201000010099 disease Diseases 0.000 description 3
• 229960005426 doxepin Drugs 0.000 description 3
• ODQWQRRAPPTVAG-GZTJUZNOSA-N doxepin Chemical compound C1OC2=CC=CC=C2C(=C/CCN(C)C)/C2=CC=CC=C21 ODQWQRRAPPTVAG-GZTJUZNOSA-N 0.000 description 3
• 229960002866 duloxetine Drugs 0.000 description 3
• 238000000835 electrochemical detection Methods 0.000 description 3
• 238000010828 elution Methods 0.000 description 3
• 229960004341 escitalopram Drugs 0.000 description 3
• WSEQXVZVJXJVFP-FQEVSTJZSA-N escitalopram Chemical compound C1([C@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WSEQXVZVJXJVFP-FQEVSTJZSA-N 0.000 description 3
• 230000008020 evaporation Effects 0.000 description 3
• 206010022437 insomnia Diseases 0.000 description 3
• IQVRBWUUXZMOPW-PKNBQFBNSA-N istradefylline Chemical compound CN1C=2C(=O)N(CC)C(=O)N(CC)C=2N=C1\C=C\C1=CC=C(OC)C(OC)=C1 IQVRBWUUXZMOPW-PKNBQFBNSA-N 0.000 description 3
• 229950009028 istradefylline Drugs 0.000 description 3
• 229960004002 levetiracetam Drugs 0.000 description 3
• HPHUVLMMVZITSG-ZCFIWIBFSA-N levetiracetam Chemical compound CC[C@H](C(N)=O)N1CCCC1=O HPHUVLMMVZITSG-ZCFIWIBFSA-N 0.000 description 3
• 238000002483 medication Methods 0.000 description 3
• 229960001785 mirtazapine Drugs 0.000 description 3
• RONZAEMNMFQXRA-UHFFFAOYSA-N mirtazapine Chemical compound C1C2=CC=CN=C2N2CCN(C)CC2C2=CC=CC=C21 RONZAEMNMFQXRA-UHFFFAOYSA-N 0.000 description 3
• UZHSEJADLWPNLE-GRGSLBFTSA-N naloxone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(O)C2=C5[C@@]13CCN4CC=C UZHSEJADLWPNLE-GRGSLBFTSA-N 0.000 description 3
• 229960004127 naloxone Drugs 0.000 description 3
• 210000005036 nerve Anatomy 0.000 description 3
• 229960001158 nortriptyline Drugs 0.000 description 3
• 229940005483 opioid analgesics Drugs 0.000 description 3
• 229960002296 paroxetine Drugs 0.000 description 3
• IENZQIKPVFGBNW-UHFFFAOYSA-N prazosin Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(CC1)CCN1C(=O)C1=CC=CO1 IENZQIKPVFGBNW-UHFFFAOYSA-N 0.000 description 3
• 229960001289 prazosin Drugs 0.000 description 3
• 239000002244 precipitate Substances 0.000 description 3
• 229960004431 quetiapine Drugs 0.000 description 3
• URKOMYMAXPYINW-UHFFFAOYSA-N quetiapine Chemical compound C1CN(CCOCCO)CCN1C1=NC2=CC=CC=C2SC2=CC=CC=C12 URKOMYMAXPYINW-UHFFFAOYSA-N 0.000 description 3
• 229960001534 risperidone Drugs 0.000 description 3
• RAPZEAPATHNIPO-UHFFFAOYSA-N risperidone Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCCC4=NC=3C)=NOC2=C1 RAPZEAPATHNIPO-UHFFFAOYSA-N 0.000 description 3
• VGKDLMBJGBXTGI-SJCJKPOMSA-N sertraline Chemical compound C1([C@@H]2CC[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 VGKDLMBJGBXTGI-SJCJKPOMSA-N 0.000 description 3
• 229960002073 sertraline Drugs 0.000 description 3
• 208000020685 sleep-wake disease Diseases 0.000 description 3
• 230000000391 smoking effect Effects 0.000 description 3
• 238000003860 storage Methods 0.000 description 3
• 238000004809 thin layer chromatography Methods 0.000 description 3
• 229960004751 varenicline Drugs 0.000 description 3
• TWYFGYXQSYOKLK-CYUSMAIQSA-N varenicline tartrate Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O.C12=CC3=NC=CN=C3C=C2[C@H]2C[C@@H]1CNC2 TWYFGYXQSYOKLK-CYUSMAIQSA-N 0.000 description 3
• 229960004688 venlafaxine Drugs 0.000 description 3
• PNVNVHUZROJLTJ-UHFFFAOYSA-N venlafaxine Chemical compound C1=CC(OC)=CC=C1C(CN(C)C)C1(O)CCCCC1 PNVNVHUZROJLTJ-UHFFFAOYSA-N 0.000 description 3
• UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 description 2
• VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
• NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 2
• DETXZQGDWUJKMO-UHFFFAOYSA-N 2-hydroxymethanesulfonic acid Chemical compound OCS(O)(=O)=O DETXZQGDWUJKMO-UHFFFAOYSA-N 0.000 description 2
• QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
• 108060003345 Adrenergic Receptor Proteins 0.000 description 2
• 102000017910 Adrenergic receptor Human genes 0.000 description 2
• 206010001605 Alcohol poisoning Diseases 0.000 description 2
• 101100499810 Bos taurus DBH gene Proteins 0.000 description 2
• 208000024172 Cardiovascular disease Diseases 0.000 description 2
• 206010010904 Convulsion Diseases 0.000 description 2
• 102000015554 Dopamine receptor Human genes 0.000 description 2
• 108050004812 Dopamine receptor Proteins 0.000 description 2
• KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
• VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 2
• 239000005977 Ethylene Substances 0.000 description 2
• ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
• DGMPVYSXXIOGJY-UHFFFAOYSA-N Fusaric acid Chemical compound CCCCC1=CC=C(C(O)=O)N=C1 DGMPVYSXXIOGJY-UHFFFAOYSA-N 0.000 description 2
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
• 108010024636 Glutathione Proteins 0.000 description 2
• HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
• 241000282412 Homo Species 0.000 description 2
• 101100499813 Homo sapiens DBH gene Proteins 0.000 description 2
• FEWJPZIEWOKRBE-JCYAYHJZSA-L L-tartrate(2-) Chemical compound [O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O FEWJPZIEWOKRBE-JCYAYHJZSA-L 0.000 description 2
• AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
• 108010074633 Mixed Function Oxygenases Proteins 0.000 description 2
• 102000008109 Mixed Function Oxygenases Human genes 0.000 description 2
• 125000003047 N-acetyl group Chemical group 0.000 description 2
• 206010029260 Neuroblastoma Diseases 0.000 description 2
• GQPLMRYTRLFLPF-UHFFFAOYSA-N Nitrous Oxide Chemical compound [O-][N+]#N GQPLMRYTRLFLPF-UHFFFAOYSA-N 0.000 description 2
• 102000004270 Peptidyl-Dipeptidase A Human genes 0.000 description 2
• 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 description 2
• 206010038743 Restlessness Diseases 0.000 description 2
• 201000001880 Sexual dysfunction Diseases 0.000 description 2
• HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 2
• 238000009825 accumulation Methods 0.000 description 2
• 230000001800 adrenalinergic effect Effects 0.000 description 2
• 201000007930 alcohol dependence Diseases 0.000 description 2
• 230000004075 alteration Effects 0.000 description 2
• 230000003110 anti-inflammatory effect Effects 0.000 description 2
• 229910052786 argon Inorganic materials 0.000 description 2
• 208000006673 asthma Diseases 0.000 description 2
• 229940125388 beta agonist Drugs 0.000 description 2
• WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
• NMJJFJNHVMGPGM-UHFFFAOYSA-N butyl formate Chemical compound CCCCOC=O NMJJFJNHVMGPGM-UHFFFAOYSA-N 0.000 description 2
• NPAKNKYSJIDKMW-UHFFFAOYSA-N carvedilol Chemical compound COC1=CC=CC=C1OCCNCC(O)COC1=CC=CC2=NC3=CC=C[CH]C3=C12 NPAKNKYSJIDKMW-UHFFFAOYSA-N 0.000 description 2
• 229960004195 carvedilol Drugs 0.000 description 2
• 229940109239 creatinine Drugs 0.000 description 2
• 238000004090 dissolution Methods 0.000 description 2
• 229940085047 disulfiram 250 mg Drugs 0.000 description 2
• 239000002552 dosage form Substances 0.000 description 2
• 230000004064 dysfunction Effects 0.000 description 2
• 230000001544 dysphoric effect Effects 0.000 description 2
• 230000008030 elimination Effects 0.000 description 2
• 238000003379 elimination reaction Methods 0.000 description 2
• 238000007824 enzymatic assay Methods 0.000 description 2
• 206010015037 epilepsy Diseases 0.000 description 2
• 150000002148 esters Chemical group 0.000 description 2
• 238000011156 evaluation Methods 0.000 description 2
• 230000007717 exclusion Effects 0.000 description 2
• 239000000284 extract Substances 0.000 description 2
• 238000001914 filtration Methods 0.000 description 2
• 230000037406 food intake Effects 0.000 description 2
• 230000000574 ganglionic effect Effects 0.000 description 2
• 229960003180 glutathione Drugs 0.000 description 2
• 239000008187 granular material Substances 0.000 description 2
• 239000001963 growth medium Substances 0.000 description 2
• 230000036541 health Effects 0.000 description 2
• 229920000669 heparin Polymers 0.000 description 2
• 229960002897 heparin Drugs 0.000 description 2
• 125000000623 heterocyclic group Chemical group 0.000 description 2
• 239000002117 illicit drug Substances 0.000 description 2
• 238000011534 incubation Methods 0.000 description 2
• 230000000977 initiatory effect Effects 0.000 description 2
• 239000010410 layer Substances 0.000 description 2
• XZEUAXYWNKYKPL-WDYNHAJCSA-N levormeloxifene Chemical compound C1([C@H]2[C@@H](C3=CC=C(C=C3OC2(C)C)OC)C=2C=CC(OCCN3CCCC3)=CC=2)=CC=CC=C1 XZEUAXYWNKYKPL-WDYNHAJCSA-N 0.000 description 2
• 238000007449 liver function test Methods 0.000 description 2
• HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
• 235000012054 meals Nutrition 0.000 description 2
• 239000002609 medium Substances 0.000 description 2
• 230000002503 metabolic effect Effects 0.000 description 2
• 239000002207 metabolite Substances 0.000 description 2
• PMRYVIKBURPHAH-UHFFFAOYSA-N methimazole Chemical compound CN1C=CNC1=S PMRYVIKBURPHAH-UHFFFAOYSA-N 0.000 description 2
• VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 2
• CXGFWBPQQXZELI-UHFFFAOYSA-N n-ethylpyridin-2-amine Chemical compound CCNC1=CC=CC=N1 CXGFWBPQQXZELI-UHFFFAOYSA-N 0.000 description 2
• 229940073569 n-methylephedrine Drugs 0.000 description 2
• 230000018791 negative regulation of catalytic activity Effects 0.000 description 2
• 230000003982 neuronal uptake Effects 0.000 description 2
• 231100000252 nontoxic Toxicity 0.000 description 2
• 230000003000 nontoxic effect Effects 0.000 description 2
• 230000002474 noradrenergic effect Effects 0.000 description 2
• 239000012044 organic layer Substances 0.000 description 2
• 239000008194 pharmaceutical composition Substances 0.000 description 2
• 208000007100 phencyclidine abuse Diseases 0.000 description 2
• 229960001802 phenylephrine Drugs 0.000 description 2
• SONNWYBIRXJNDC-VIFPVBQESA-N phenylephrine Chemical compound CNC[C@H](O)C1=CC=CC(O)=C1 SONNWYBIRXJNDC-VIFPVBQESA-N 0.000 description 2
• 239000006187 pill Substances 0.000 description 2
• 230000012495 positive regulation of renal sodium excretion Effects 0.000 description 2
• 230000035935 pregnancy Effects 0.000 description 2
• 230000036584 pressor response Effects 0.000 description 2
• 150000003140 primary amides Chemical class 0.000 description 2
• 229960003712 propranolol Drugs 0.000 description 2
• 238000001671 psychotherapy Methods 0.000 description 2
• 210000001147 pulmonary artery Anatomy 0.000 description 2
• 239000013062 quality control Sample Substances 0.000 description 2
• 230000000284 resting effect Effects 0.000 description 2
• 239000000837 restrainer Substances 0.000 description 2
• 210000002966 serum Anatomy 0.000 description 2
• 231100000872 sexual dysfunction Toxicity 0.000 description 2
• 230000001568 sexual effect Effects 0.000 description 2
• 230000007958 sleep Effects 0.000 description 2
• 230000000638 stimulation Effects 0.000 description 2
• 239000012089 stop solution Substances 0.000 description 2
• 230000035900 sweating Effects 0.000 description 2
• 239000003826 tablet Substances 0.000 description 2
• 229940095064 tartrate Drugs 0.000 description 2
• ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 2
• 229960002178 thiamazole Drugs 0.000 description 2
• ZMZDMBWJUHKJPS-UHFFFAOYSA-N thiocyanic acid Chemical compound SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 2
• 238000004448 titration Methods 0.000 description 2
• 229960002431 trimipramine Drugs 0.000 description 2
• ZSCDBOWYZJWBIY-UHFFFAOYSA-N trimipramine Chemical compound C1CC2=CC=CC=C2N(CC(CN(C)C)C)C2=CC=CC=C21 ZSCDBOWYZJWBIY-UHFFFAOYSA-N 0.000 description 2
• 238000000825 ultraviolet detection Methods 0.000 description 2
• 230000024883 vasodilation Effects 0.000 description 2
• 210000003462 vein Anatomy 0.000 description 2
• 230000000007 visual effect Effects 0.000 description 2
• 239000000341 volatile oil Substances 0.000 description 2
• KEIFWROAQVVDBN-UHFFFAOYSA-N 1,2-dihydronaphthalene Chemical compound C1=CC=C2C=CCCC2=C1 KEIFWROAQVVDBN-UHFFFAOYSA-N 0.000 description 1
• XHLHPRDBBAGVEG-UHFFFAOYSA-N 1-tetralone Chemical compound C1=CC=C2C(=O)CCCC2=C1 XHLHPRDBBAGVEG-UHFFFAOYSA-N 0.000 description 1
• ZIIUUSVHCHPIQD-UHFFFAOYSA-N 2,4,6-trimethyl-N-[3-(trifluoromethyl)phenyl]benzenesulfonamide Chemical compound CC1=CC(C)=CC(C)=C1S(=O)(=O)NC1=CC=CC(C(F)(F)F)=C1 ZIIUUSVHCHPIQD-UHFFFAOYSA-N 0.000 description 1
• YFMPSMITLLBENU-UHFFFAOYSA-N 3,4-dihydroxybenzylamine Chemical compound NCC1=CC=C(O)C(O)=C1 YFMPSMITLLBENU-UHFFFAOYSA-N 0.000 description 1
• ZKPVULIWDZEZIT-UHFFFAOYSA-N 3-(1-ethyl-3,4-dihydronaphthalen-2-yl)pyridine Chemical compound C1CC2=CC=CC=C2C(CC)=C1C1=CC=CN=C1 ZKPVULIWDZEZIT-UHFFFAOYSA-N 0.000 description 1
• UIAGMCDKSXEBJQ-IBGZPJMESA-N 3-o-(2-methoxyethyl) 5-o-propan-2-yl (4s)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound COCCOC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)[C@H]1C1=CC=CC([N+]([O-])=O)=C1 UIAGMCDKSXEBJQ-IBGZPJMESA-N 0.000 description 1
• HOUVATQQKYAEBB-UHFFFAOYSA-N 5,7-difluoro-3,4-dihydro-1h-naphthalen-2-one Chemical compound C1CC(=O)CC2=CC(F)=CC(F)=C21 HOUVATQQKYAEBB-UHFFFAOYSA-N 0.000 description 1
• 102000006902 5-HT2C Serotonin Receptor Human genes 0.000 description 1
• 108010072553 5-HT2C Serotonin Receptor Proteins 0.000 description 1
• 208000030507 AIDS Diseases 0.000 description 1
• 102000008146 Acetate-CoA ligase Human genes 0.000 description 1
• 108010049926 Acetate-CoA ligase Proteins 0.000 description 1
• 102100022715 Acetyl-coenzyme A thioesterase Human genes 0.000 description 1
• 102000057234 Acyl transferases Human genes 0.000 description 1
• 108700016155 Acyl transferases Proteins 0.000 description 1
• 206010067484 Adverse reaction Diseases 0.000 description 1
• 241000478345 Afer Species 0.000 description 1
• PQSUYGKTWSAVDQ-ZVIOFETBSA-N Aldosterone Chemical compound C([C@@]1([C@@H](C(=O)CO)CC[C@H]1[C@@H]1CC2)C=O)[C@H](O)[C@@H]1[C@]1(C)C2=CC(=O)CC1 PQSUYGKTWSAVDQ-ZVIOFETBSA-N 0.000 description 1
• PQSUYGKTWSAVDQ-UHFFFAOYSA-N Aldosterone Natural products C1CC2C3CCC(C(=O)CO)C3(C=O)CC(O)C2C2(C)C1=CC(=O)CC2 PQSUYGKTWSAVDQ-UHFFFAOYSA-N 0.000 description 1
• 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
• 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
• GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
• 108010064733 Angiotensins Proteins 0.000 description 1
• 102000015427 Angiotensins Human genes 0.000 description 1
• 244000080767 Areca catechu Species 0.000 description 1
• 206010003130 Arrhythmia supraventricular Diseases 0.000 description 1
• 229930003347 Atropine Natural products 0.000 description 1
• KZFBHCCLJSAHBQ-UHFFFAOYSA-N Benzoylecgonine Natural products CN1C2CCC1C(C(C2)OC(=C)c3ccccc3)C(=O)O KZFBHCCLJSAHBQ-UHFFFAOYSA-N 0.000 description 1
• 206010006582 Bundle branch block right Diseases 0.000 description 1
• 206010006578 Bundle-Branch Block Diseases 0.000 description 1
• BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
• 241000282693 Cercopithecidae Species 0.000 description 1
• 108090001069 Chymopapain Proteins 0.000 description 1
• XXAXVMUWHZHZMJ-UHFFFAOYSA-N Chymopapain Chemical compound OC1=CC(S(O)(=O)=O)=CC(S(O)(=O)=O)=C1O XXAXVMUWHZHZMJ-UHFFFAOYSA-N 0.000 description 1
• KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
• 208000017781 Cocaine intoxication Diseases 0.000 description 1
• 208000035473 Communicable disease Diseases 0.000 description 1
• RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
• 102000010906 Cyclooxygenase 1 Human genes 0.000 description 1
• 108010037464 Cyclooxygenase 1 Proteins 0.000 description 1
• 238000007400 DNA extraction Methods 0.000 description 1
• 206010012225 Delirium tremens Diseases 0.000 description 1
• 206010012374 Depressed mood Diseases 0.000 description 1
• 206010012735 Diarrhoea Diseases 0.000 description 1
• 206010013710 Drug interaction Diseases 0.000 description 1
• 206010013754 Drug withdrawal syndrome Diseases 0.000 description 1
• 108060002716 Exonuclease Proteins 0.000 description 1
• 238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 1
• 238000005727 Friedel-Crafts reaction Methods 0.000 description 1
• 108010010803 Gelatin Proteins 0.000 description 1
• 208000034308 Grand mal convulsion Diseases 0.000 description 1
• 208000031886 HIV Infections Diseases 0.000 description 1
• 206010019070 Hallucination, auditory Diseases 0.000 description 1
• 101000678862 Homo sapiens Acetyl-coenzyme A thioesterase Proteins 0.000 description 1
• 101000939500 Homo sapiens UBX domain-containing protein 11 Proteins 0.000 description 1
• UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
• 108090000895 Hydroxymethylglutaryl CoA Reductases Proteins 0.000 description 1
• 102000004286 Hydroxymethylglutaryl CoA Reductases Human genes 0.000 description 1
• RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 description 1
• 208000001953 Hypotension Diseases 0.000 description 1
• FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
• GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
• 241000124008 Mammalia Species 0.000 description 1
• 208000003863 Marijuana Abuse Diseases 0.000 description 1
• 241000252067 Megalops atlanticus Species 0.000 description 1
• 241000699666 Mus <mouse, genus> Species 0.000 description 1
• 102000014415 Muscarinic acetylcholine receptor Human genes 0.000 description 1
• 108050003473 Muscarinic acetylcholine receptor Proteins 0.000 description 1
• 208000000112 Myalgia Diseases 0.000 description 1
• 229910002651 NO3 Inorganic materials 0.000 description 1
• 108090000028 Neprilysin Proteins 0.000 description 1
• 102000003729 Neprilysin Human genes 0.000 description 1
• 208000012902 Nervous system disease Diseases 0.000 description 1
• 208000025966 Neurological disease Diseases 0.000 description 1
• NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
• 102000008299 Nitric Oxide Synthase Human genes 0.000 description 1
• 108010021487 Nitric Oxide Synthase Proteins 0.000 description 1
• 102000003840 Opioid Receptors Human genes 0.000 description 1
• 108090000137 Opioid Receptors Proteins 0.000 description 1
• 240000007594 Oryza sativa Species 0.000 description 1
• 235000007164 Oryza sativa Nutrition 0.000 description 1
• 229910019142 PO4 Inorganic materials 0.000 description 1
• 208000002193 Pain Diseases 0.000 description 1
• KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium on carbon Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 1
• 206010033864 Paranoia Diseases 0.000 description 1
• 208000027099 Paranoid disease Diseases 0.000 description 1
• 235000019483 Peanut oil Nutrition 0.000 description 1
• 108010064785 Phospholipases Proteins 0.000 description 1
• 102000015439 Phospholipases Human genes 0.000 description 1
• 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 description 1
• 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 description 1
• 206010035039 Piloerection Diseases 0.000 description 1
• 208000004880 Polyuria Diseases 0.000 description 1
• 241001282135 Poromitra oscitans Species 0.000 description 1
• XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
• 102000001253 Protein Kinase Human genes 0.000 description 1
• 102000003923 Protein Kinase C Human genes 0.000 description 1
• 108090000315 Protein Kinase C Proteins 0.000 description 1
• 206010037211 Psychomotor hyperactivity Diseases 0.000 description 1
• 206010039101 Rhinorrhoea Diseases 0.000 description 1
• 241000283984 Rodentia Species 0.000 description 1
• 229940124639 Selective inhibitor Drugs 0.000 description 1
• VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
• DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
• 229920002472 Starch Polymers 0.000 description 1
• 238000007059 Strecker synthesis reaction Methods 0.000 description 1
• 229930006000 Sucrose Natural products 0.000 description 1
• CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
• 206010042458 Suicidal ideation Diseases 0.000 description 1
• 206010042464 Suicide attempt Diseases 0.000 description 1
• 239000000150 Sympathomimetic Substances 0.000 description 1
• 102100035115 Testin Human genes 0.000 description 1
• 101710070533 Testin Proteins 0.000 description 1
• 238000008050 Total Bilirubin Reagent Methods 0.000 description 1
• 229940123468 Transferase inhibitor Drugs 0.000 description 1
• 102000004357 Transferases Human genes 0.000 description 1
• 108090000992 Transferases Proteins 0.000 description 1
• 108091000117 Tyrosine 3-Monooxygenase Proteins 0.000 description 1
• 102000048218 Tyrosine 3-monooxygenases Human genes 0.000 description 1
• 102100029645 UBX domain-containing protein 11 Human genes 0.000 description 1
• 208000021017 Weight Gain Diseases 0.000 description 1
• 206010048232 Yawning Diseases 0.000 description 1
• 238000010521 absorption reaction Methods 0.000 description 1
• 230000002378 acidificating effect Effects 0.000 description 1
• 150000007513 acids Chemical class 0.000 description 1
• 125000002252 acyl group Chemical group 0.000 description 1
• 230000001919 adrenal effect Effects 0.000 description 1
• 210000004100 adrenal gland Anatomy 0.000 description 1
• 230000006838 adverse reaction Effects 0.000 description 1
• 230000008484 agonism Effects 0.000 description 1
• 206010001584 alcohol abuse Diseases 0.000 description 1
• 208000025746 alcohol use disease Diseases 0.000 description 1
• 208000006246 alcohol withdrawal delirium Diseases 0.000 description 1
• 208000028505 alcohol-related disease Diseases 0.000 description 1
• 229960002478 aldosterone Drugs 0.000 description 1
• 230000001668 ameliorated effect Effects 0.000 description 1
• 125000005219 aminonitrile group Chemical group 0.000 description 1
• 201000002472 amphetamine abuse Diseases 0.000 description 1
• 230000036592 analgesia Effects 0.000 description 1
• 239000000538 analytical sample Substances 0.000 description 1
• 238000010171 animal model Methods 0.000 description 1
• 230000003466 anti-cipated effect Effects 0.000 description 1
• 230000000798 anti-retroviral effect Effects 0.000 description 1
• 229940127088 antihypertensive drug Drugs 0.000 description 1
• 239000003963 antioxidant agent Substances 0.000 description 1
• 235000006708 antioxidants Nutrition 0.000 description 1
• 239000008346 aqueous phase Substances 0.000 description 1
• 229940127225 asthma medication Drugs 0.000 description 1
• 239000012298 atmosphere Substances 0.000 description 1
• RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 description 1
• 229960000396 atropine Drugs 0.000 description 1
• 238000011952 auditory verbal learning test Methods 0.000 description 1
• 238000013475 authorization Methods 0.000 description 1
• 230000001363 autoimmune Effects 0.000 description 1
• 230000002567 autonomic effect Effects 0.000 description 1
• 235000013405 beer Nutrition 0.000 description 1
• 230000009286 beneficial effect Effects 0.000 description 1
• WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
• 235000013361 beverage Nutrition 0.000 description 1
• 239000012472 biological sample Substances 0.000 description 1
• 230000008499 blood brain barrier function Effects 0.000 description 1
• 238000010241 blood sampling Methods 0.000 description 1
• 210000001218 blood-brain barrier Anatomy 0.000 description 1
• 238000009835 boiling Methods 0.000 description 1
• 208000029028 brain injury Diseases 0.000 description 1
• 239000000872 buffer Substances 0.000 description 1
• 239000011575 calcium Substances 0.000 description 1
• 238000004364 calculation method Methods 0.000 description 1
• 201000001843 cannabis dependence Diseases 0.000 description 1
• 239000001569 carbon dioxide Substances 0.000 description 1
• 229910002092 carbon dioxide Inorganic materials 0.000 description 1
• 235000011089 carbon dioxide Nutrition 0.000 description 1
• RBHJBMIOOPYDBQ-UHFFFAOYSA-N carbon dioxide;propan-2-one Chemical compound O=C=O.CC(C)=O RBHJBMIOOPYDBQ-UHFFFAOYSA-N 0.000 description 1
• 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
• 230000007681 cardiovascular toxicity Effects 0.000 description 1
• 231100000060 cardiovascular toxicity Toxicity 0.000 description 1
• 239000000969 carrier Substances 0.000 description 1
• 239000001913 cellulose Substances 0.000 description 1
• 229920002678 cellulose Polymers 0.000 description 1
• 210000003169 central nervous system Anatomy 0.000 description 1
• 239000013522 chelant Substances 0.000 description 1
• 238000000451 chemical ionisation Methods 0.000 description 1
• 231100000762 chronic effect Toxicity 0.000 description 1
• 235000019506 cigar Nutrition 0.000 description 1
• 235000019504 cigarettes Nutrition 0.000 description 1
• 230000007012 clinical effect Effects 0.000 description 1
• 238000009535 clinical urine test Methods 0.000 description 1
• 230000019771 cognition Effects 0.000 description 1
• 239000003086 colorant Substances 0.000 description 1
• 239000012230 colorless oil Substances 0.000 description 1
• 230000002860 competitive effect Effects 0.000 description 1
• 239000002131 composite material Substances 0.000 description 1
• 229940125782 compound 2 Drugs 0.000 description 1
• 230000009989 contractile response Effects 0.000 description 1
• 229910052802 copper Inorganic materials 0.000 description 1
• 239000010949 copper Substances 0.000 description 1
• 229910000366 copper(II) sulfate Inorganic materials 0.000 description 1
• 239000013078 crystal Substances 0.000 description 1
• 101150109673 dbh gene Proteins 0.000 description 1
• 230000002950 deficient Effects 0.000 description 1
• 230000000881 depressing effect Effects 0.000 description 1
• 230000000994 depressogenic effect Effects 0.000 description 1
• 238000001514 detection method Methods 0.000 description 1
• 230000006866 deterioration Effects 0.000 description 1
• 239000008121 dextrose Substances 0.000 description 1
• 238000003745 diagnosis Methods 0.000 description 1
• 230000010339 dilation Effects 0.000 description 1
• 239000001177 diphosphate Substances 0.000 description 1
• XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
• 235000011180 diphosphates Nutrition 0.000 description 1
• 230000035619 diuresis Effects 0.000 description 1
• 229940052760 dopamine agonists Drugs 0.000 description 1
• 229940000406 drug candidate Drugs 0.000 description 1
• 239000003937 drug carrier Substances 0.000 description 1
• 230000000857 drug effect Effects 0.000 description 1
• 238000001035 drying Methods 0.000 description 1
• GVGYEFKIHJTNQZ-RFQIPJPRSA-N ecgonine benzoate Chemical compound O([C@@H]1[C@@H]([C@H]2CC[C@@H](C1)N2C)C(O)=O)C(=O)C1=CC=CC=C1 GVGYEFKIHJTNQZ-RFQIPJPRSA-N 0.000 description 1
• 239000003792 electrolyte Substances 0.000 description 1
• 239000003995 emulsifying agent Substances 0.000 description 1
• 230000002255 enzymatic effect Effects 0.000 description 1
• 208000028329 epileptic seizure Diseases 0.000 description 1
• 150000002170 ethers Chemical class 0.000 description 1
• 125000000816 ethylene group Chemical group [H]C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
• 230000002743 euphoric effect Effects 0.000 description 1
• 230000005713 exacerbation Effects 0.000 description 1
• 102000013165 exonuclease Human genes 0.000 description 1
• 238000000605 extraction Methods 0.000 description 1
• 238000004992 fast atom bombardment mass spectroscopy Methods 0.000 description 1
• 210000003608 fece Anatomy 0.000 description 1
• 239000000796 flavoring agent Substances 0.000 description 1
• 235000019634 flavors Nutrition 0.000 description 1
• 235000013312 flour Nutrition 0.000 description 1
• 238000011010 flushing procedure Methods 0.000 description 1
• 235000003599 food sweetener Nutrition 0.000 description 1
• WBJINCZRORDGAQ-UHFFFAOYSA-N formic acid ethyl ester Natural products CCOC=O WBJINCZRORDGAQ-UHFFFAOYSA-N 0.000 description 1
• 238000003304 gavage Methods 0.000 description 1
• 239000008273 gelatin Substances 0.000 description 1
• 229920000159 gelatin Polymers 0.000 description 1
• 235000019322 gelatine Nutrition 0.000 description 1
• 235000011852 gelatine desserts Nutrition 0.000 description 1
• 102000054766 genetic haplotypes Human genes 0.000 description 1
• 238000003205 genotyping method Methods 0.000 description 1
• 239000008103 glucose Substances 0.000 description 1
• 229930182480 glucuronide Natural products 0.000 description 1
• 150000008134 glucuronides Chemical class 0.000 description 1
• YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
• SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
• 150000002334 glycols Chemical class 0.000 description 1
• 244000144993 groups of animals Species 0.000 description 1
• 230000036433 growing body Effects 0.000 description 1
• 208000019622 heart disease Diseases 0.000 description 1
• 238000010438 heat treatment Methods 0.000 description 1
• 230000002440 hepatic effect Effects 0.000 description 1
• AKRQHOWXVSDJEF-UHFFFAOYSA-N heptane-1-sulfonic acid Chemical compound CCCCCCCS(O)(=O)=O AKRQHOWXVSDJEF-UHFFFAOYSA-N 0.000 description 1
• 230000013632 homeostatic process Effects 0.000 description 1
• 239000012456 homogeneous solution Substances 0.000 description 1
• 150000004677 hydrates Chemical group 0.000 description 1
• 239000001257 hydrogen Substances 0.000 description 1
• 229910052739 hydrogen Inorganic materials 0.000 description 1
• 230000007062 hydrolysis Effects 0.000 description 1
• 238000006460 hydrolysis reaction Methods 0.000 description 1
• ARRNBPCNZJXHRJ-UHFFFAOYSA-M hydron;tetrabutylazanium;phosphate Chemical compound OP(O)([O-])=O.CCCC[N+](CCCC)(CCCC)CCCC ARRNBPCNZJXHRJ-UHFFFAOYSA-M 0.000 description 1
• DOUHZFSGSXMPIE-UHFFFAOYSA-N hydroxidooxidosulfur(.) Chemical compound [O]SO DOUHZFSGSXMPIE-UHFFFAOYSA-N 0.000 description 1
• 208000013403 hyperactivity Diseases 0.000 description 1
• 230000036543 hypotension Effects 0.000 description 1
• 230000006698 induction Effects 0.000 description 1
• 239000011261 inert gas Substances 0.000 description 1
• 208000015181 infectious disease Diseases 0.000 description 1
• 230000030214 innervation Effects 0.000 description 1
• 238000007918 intramuscular administration Methods 0.000 description 1
• 238000010829 isocratic elution Methods 0.000 description 1
• 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
• 150000002576 ketones Chemical class 0.000 description 1
• 230000003907 kidney function Effects 0.000 description 1
• 238000009592 kidney function test Methods 0.000 description 1
• 238000009533 lab test Methods 0.000 description 1
• 239000008101 lactose Substances 0.000 description 1
• 238000010150 least significant difference test Methods 0.000 description 1
• 208000013433 lightheadedness Diseases 0.000 description 1
• 230000000670 limiting effect Effects 0.000 description 1
• 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
• 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 1
• 230000007774 longterm Effects 0.000 description 1
• 235000019359 magnesium stearate Nutrition 0.000 description 1
• 208000024714 major depressive disease Diseases 0.000 description 1
• 229940049920 malate Drugs 0.000 description 1
• BJEPYKJPYRNKOW-UHFFFAOYSA-L malate(2-) Chemical compound [O-]C(=O)C(O)CC([O-])=O BJEPYKJPYRNKOW-UHFFFAOYSA-L 0.000 description 1
• VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
• 230000000873 masking effect Effects 0.000 description 1
• 238000001819 mass spectrum Methods 0.000 description 1
• 239000000463 material Substances 0.000 description 1
• 230000010534 mechanism of action Effects 0.000 description 1
• 230000001404 mediated effect Effects 0.000 description 1
• 238000002844 melting Methods 0.000 description 1
• 230000008018 melting Effects 0.000 description 1
• 239000012528 membrane Substances 0.000 description 1
• 229930182817 methionine Natural products 0.000 description 1
• 239000002480 mineral oil Substances 0.000 description 1
• 235000010446 mineral oil Nutrition 0.000 description 1
• 150000007522 mineralic acids Chemical class 0.000 description 1
• 230000008035 nerve activity Effects 0.000 description 1
• 230000007383 nerve stimulation Effects 0.000 description 1
• 230000001537 neural effect Effects 0.000 description 1
• 230000000955 neuroendocrine Effects 0.000 description 1
• 230000002644 neurohormonal effect Effects 0.000 description 1
• 230000000926 neurological effect Effects 0.000 description 1
• 210000002569 neuron Anatomy 0.000 description 1
• 230000007935 neutral effect Effects 0.000 description 1
• 238000002670 nicotine replacement therapy Methods 0.000 description 1
• 229960000715 nimodipine Drugs 0.000 description 1
• 239000001272 nitrous oxide Substances 0.000 description 1
• 230000000474 nursing effect Effects 0.000 description 1
• QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
• 229940127240 opiate Drugs 0.000 description 1
• 201000000988 opioid abuse Diseases 0.000 description 1
• 230000003287 optical effect Effects 0.000 description 1
• 150000007524 organic acids Chemical class 0.000 description 1
• 150000002894 organic compounds Chemical class 0.000 description 1
• 239000003960 organic solvent Substances 0.000 description 1
• 230000003204 osmotic effect Effects 0.000 description 1
• 230000036407 pain Effects 0.000 description 1
• 239000000312 peanut oil Substances 0.000 description 1
• 239000003208 petroleum Substances 0.000 description 1
• 229940124531 pharmaceutical excipient Drugs 0.000 description 1
• 239000000825 pharmaceutical preparation Substances 0.000 description 1
• 230000003285 pharmacodynamic effect Effects 0.000 description 1
• 239000010452 phosphate Substances 0.000 description 1
• NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
• 230000005371 pilomotor reflex Effects 0.000 description 1
• 239000013641 positive control Substances 0.000 description 1
• 231100000683 possible toxicity Toxicity 0.000 description 1
• LJCNRYVRMXRIQR-OLXYHTOASA-L potassium sodium L-tartrate Chemical compound [Na+].[K+].[O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O LJCNRYVRMXRIQR-OLXYHTOASA-L 0.000 description 1
• ZNNZYHKDIALBAK-UHFFFAOYSA-M potassium thiocyanate Chemical compound [K+].[S-]C#N ZNNZYHKDIALBAK-UHFFFAOYSA-M 0.000 description 1
• CUQOHAYJWVTKDE-UHFFFAOYSA-N potassium;butan-1-olate Chemical compound [K+].CCCC[O-] CUQOHAYJWVTKDE-UHFFFAOYSA-N 0.000 description 1
• 239000000955 prescription drug Substances 0.000 description 1
• 239000003755 preservative agent Substances 0.000 description 1
• 230000003518 presynaptic effect Effects 0.000 description 1
• 230000002265 prevention Effects 0.000 description 1
• 229930010796 primary metabolite Natural products 0.000 description 1
• 230000037452 priming Effects 0.000 description 1
• 229940002612 prodrug Drugs 0.000 description 1
• 239000000651 prodrug Chemical group 0.000 description 1
• 230000000750 progressive effect Effects 0.000 description 1
• 108060006633 protein kinase Proteins 0.000 description 1
• 102000004169 proteins and genes Human genes 0.000 description 1
• 108090000623 proteins and genes Proteins 0.000 description 1
• 229940001470 psychoactive drug Drugs 0.000 description 1
• 238000011002 quantification Methods 0.000 description 1
• 238000003653 radioligand binding assay Methods 0.000 description 1
• 238000003753 real-time PCR Methods 0.000 description 1
• 238000004064 recycling Methods 0.000 description 1
• 230000036454 renin-angiotensin system Effects 0.000 description 1
• 230000000241 respiratory effect Effects 0.000 description 1
• 230000004043 responsiveness Effects 0.000 description 1
• 238000004007 reversed phase HPLC Methods 0.000 description 1
• 230000033764 rhythmic process Effects 0.000 description 1
• 235000009566 rice Nutrition 0.000 description 1
• 201000007916 right bundle branch block Diseases 0.000 description 1
• YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
• 229960001860 salicylate Drugs 0.000 description 1
• 239000012047 saturated solution Substances 0.000 description 1
• 201000000980 schizophrenia Diseases 0.000 description 1
• 230000003248 secreting effect Effects 0.000 description 1
• 239000000741 silica gel Substances 0.000 description 1
• 229910002027 silica gel Inorganic materials 0.000 description 1
• 238000011947 six minute walk test Methods 0.000 description 1
• 235000020183 skimmed milk Nutrition 0.000 description 1
• 239000002002 slurry Substances 0.000 description 1
• 150000003384 small molecules Chemical class 0.000 description 1
• 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
• RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 1
• 239000001476 sodium potassium tartrate Substances 0.000 description 1
• 235000011006 sodium potassium tartrate Nutrition 0.000 description 1
• 239000012453 solvate Chemical group 0.000 description 1
• 238000000527 sonication Methods 0.000 description 1
• 239000003549 soybean oil Substances 0.000 description 1
• 235000012424 soybean oil Nutrition 0.000 description 1
• 241000894007 species Species 0.000 description 1
• 239000000934 spermatocidal agent Substances 0.000 description 1
• 210000000278 spinal cord Anatomy 0.000 description 1
• 238000012453 sprague-dawley rat model Methods 0.000 description 1
• 239000003381 stabilizer Substances 0.000 description 1
• 239000008107 starch Substances 0.000 description 1
• 235000019698 starch Nutrition 0.000 description 1
• 230000000707 stereoselective effect Effects 0.000 description 1
• 239000000021 stimulant Substances 0.000 description 1
• 230000004936 stimulating effect Effects 0.000 description 1
• KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
• 239000005720 sucrose Substances 0.000 description 1
• 239000006228 supernatant Substances 0.000 description 1
• 239000000829 suppository Substances 0.000 description 1
• 238000013268 sustained release Methods 0.000 description 1
• 239000012730 sustained-release form Substances 0.000 description 1
• 239000003765 sweetening agent Substances 0.000 description 1
• 230000001975 sympathomimetic effect Effects 0.000 description 1
• 229940064707 sympathomimetics Drugs 0.000 description 1
• 210000002504 synaptic vesicle Anatomy 0.000 description 1
• 208000011580 syndromic disease Diseases 0.000 description 1
• 230000009885 systemic effect Effects 0.000 description 1
• 239000000454 talc Substances 0.000 description 1
• 229910052623 talc Inorganic materials 0.000 description 1
• 238000004885 tandem mass spectrometry Methods 0.000 description 1
• CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 1
• 229960000278 theophylline Drugs 0.000 description 1
• 235000019505 tobacco product Nutrition 0.000 description 1
• JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
• 231100000419 toxicity Toxicity 0.000 description 1
• 230000001988 toxicity Effects 0.000 description 1
• 238000013518 transcription Methods 0.000 description 1
• 230000035897 transcription Effects 0.000 description 1
• 239000003558 transferase inhibitor Substances 0.000 description 1
• 238000001665 trituration Methods 0.000 description 1
• JFJZZMVDLULRGK-URLMMPGGSA-O tubocurarine Chemical compound C([C@H]1[N+](C)(C)CCC=2C=C(C(=C(OC3=CC=C(C=C3)C[C@H]3C=4C=C(C(=CC=4CCN3C)OC)O3)C=21)O)OC)C1=CC=C(O)C3=C1 JFJZZMVDLULRGK-URLMMPGGSA-O 0.000 description 1
• 229960001844 tubocurarine Drugs 0.000 description 1
• 238000002211 ultraviolet spectrum Methods 0.000 description 1
• 230000002485 urinary effect Effects 0.000 description 1
• 230000002792 vascular Effects 0.000 description 1
• 210000005166 vasculature Anatomy 0.000 description 1
• 235000013311 vegetables Nutrition 0.000 description 1
• 239000003039 volatile agent Substances 0.000 description 1
• 238000010792 warming Methods 0.000 description 1
• 238000005406 washing Methods 0.000 description 1
• 230000003442 weekly effect Effects 0.000 description 1
• 230000004584 weight gain Effects 0.000 description 1
• 235000019786 weight gain Nutrition 0.000 description 1
• 239000000080 wetting agent Substances 0.000 description 1